When regulatory cooperation goes too far, we all lose

Pharmaceutical regulators took more risks in 2021 than perhaps they normally might. Decisions around vaccines and antivirals for Covid-19 were definitely expedited, and that fact was distorted by anti-vaccine campaigners seeking to sow doubt. But the decisions were generally backed by solid evidence and independent scientific advice. The same cannot be said of the US Food and Drug Administration’s (FDA) approval of an antibody to treat Alzheimer’s disease in June.